Skip to main content

Table 4 Frequency of drug related adverse effects among patients in each group

From: A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome

Adverse effects
N (%)
Group P- value
Mirtazapine (N = 34) Placebo (N = 33)
Drowsiness 12 (35.3%) 3 (9.1%) 0.01
Dizziness 6 (17.6%) 2 (6.1%) 0.25
Nausea 5 (14.7%) 2 (6.1%) 0.43
Dry mouth 9 (26.5%) 2 (6.1%) 0.04
Fatigue 10 (29.4%) 2 (6.1%) 0.02
Headache 4 (11.8%) 1 (3.0%) 0.36
Increased appetite 11 (32.4%) 2 (6.1%) 0.01
Weight gain 8 (23.5%) 1 (3.0%) 0.03